TNF and obesity disorder: Very recently a large prospective cohort study including 955 infliximab-treated and 655 adalimumab-treated anti-TNF naïve patients with active luminal CD [107] investigated possible predictors of therapy failure: at multivariate analysis low drug concentration at week 14 was the only factor independently associated for both drugs with therapy failure at week 14 and 54, while smoking and obesity were significantly associated with treatment failure at week 54 only for adalimumab.